Nymox Pharmaceutical (NYMX +0.6%) ticks up after saying that Phase 3 immunogenicity trials of its lead drug candidate NX-1207 have not shown any evidence of eliciting an immune reaction in men treated with intraprostatic injections of the drug.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs